Shares of Bausch Health Companies Inc. (TSE:BHC – Get Free Report) reached a new 52-week high during trading on Wednesday. The stock traded as high as C$12.66 and last traded at C$12.61, with a volume of 325,307 shares traded. The stock had previously closed at C$12.10.
Bausch Health Companies News Roundup
Here’s some of the latest news about BHC:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $7.11 from $5.95 and its FY2027 estimate to $5.56 from $5.40. It also lifted estimates for several quarters in late 2026 and 2027, and nudged FY2028 EPS to $4.32 from $4.28. These upward revisions suggest improved expectations for much of the forecast period. Bausch Health Companies analyst estimates
- Negative Sentiment: Zacks lowered its Q3 2028 EPS estimate to $1.02 from $1.14, tempering the more favorable revisions elsewhere. The overall outlook remains mixed, and the estimate changes alone do not establish the reason for the share decline. Bausch Health Companies analyst estimates
Bausch Health Companies Trading Down 4.0%
The company has a debt-to-equity ratio of -1,559.86, a current ratio of 1.56 and a quick ratio of 0.58. The business’s 50 day moving average price is C$9.55 and its 200-day moving average price is C$8.16. The firm has a market capitalization of C$4.42 billion, a price-to-earnings ratio of -5.23, a price-to-earnings-growth ratio of 0.21 and a beta of 0.73.
Bausch Health Companies (TSE:BHC – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported C$2.52 EPS for the quarter. Bausch Health Companies had a negative net margin of 7.43% and a positive return on equity of 57.67%. The firm had revenue of C$4.19 billion during the quarter. Equities analysts forecast that Bausch Health Companies Inc. will post 5.55 EPS for the current fiscal year.
Bausch Health Companies announced that its board has authorized a stock buyback plan on Wednesday, October 28th that permits the company to buy back C$70 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 1.9% of its shares through open market purchases. Share repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.
Insider Activity
In related news, insider Mirza Dautbegovic sold 20,000 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the completion of the transaction, the insider directly owned 224,745 shares in the company, valued at C$2,512,649.10. The trade was a 8.17% decrease in their position. 11.28% of the stock is owned by company insiders.
Bausch Health Companies Company Profile
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Recommended Stories
- Five stocks we like better than Bausch Health Companies
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
